NIKKEI 225
25,527.37-106.93(-0.42%)HANG SENG
26,486.20+34.66(+0.13%)CRUDE OIL
43.02+0.60(+1.41%)
Oxford BioMedica plc (OXB.L)
| Previous close | 868.00 |
| Open | 883.00 |
| Bid | 857.00 x 0 |
| Ask | 859.00 x 0 |
| Day's range | 833.00 - 883.00 |
| 52-week range | 356.73 - 899.00 |
| Volume | 482,079 |
| Avg. volume | 173,478 |
| Market cap | 698.927M |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -16.40 |
| Earnings date | 17 Sep 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,085.99 |
- Globe Newswire
Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director
Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that, with effect from 1 December 2020, Dr. Siyamak (“Sam”) Rasty has been appointed to the Group’s Board as a Non-Executive Director. Dr. Rasty brings more than 20 years of leadership experience in biopharma R&D, commercial, business development, strategy and operations at global large and medium-sized pharmaceutical and early stage, private biotechnology companies. He is currently the President and Chief Executive Officer of PlateletBio, a US-based pioneering cell-based therapeutics company. Previously, he served as Chief Operating Officer at Homology Medicines, Inc., a genetic medicines company that he helped launch in 2016, having played a key role in transforming the company from a private start-up to an established, fully integrated public gene therapy and gene editing company. Prior to joining Homology, he held senior positions at Shire Pharmaceuticals, including as Vice President and Head of New Products, Director of Corporate Development at Endo Pharmaceuticals, and Director of Portfolio Management, Business & Commercial Analysis and Global Commercial Strategy at GlaxoSmithKline. Dr. Rasty holds a Ph.D. in Biochemistry from Louisiana State University, where he focused on transcriptional regulation of lentiviruses, completed a postdoctoral fellowship in Molecular Genetics and Biochemistry at the University of Pittsburgh School of Medicine, and received an MBA from Villanova University. There are no disclosures required to be made in accordance with LR 9.6.13R. Dr. Roch Doliveux, Non-Executive Chairman of Oxford Biomedica, said: “We are delighted that Sam is joining our Board of Directors. He brings significant experience to the Group from both his CEO role at PlateletBio and his previous COO role at Homology, both in the US. Having already been involved in building and growing successful gene and cell therapy companies, Sam brings an invaluable combination of leadership, strategy and operational knowledge to the Board at this important time.” Dr. Sam Rasty added: “Gene and cell therapies are the new frontier in medicine, addressing previously untreatable human diseases and revolutionising treatment paradigms for patients. As such, I am delighted to be joining the Board of Oxford Biomedica, a Group that has played a central role in key innovations in gene therapy and development of the industry.” -Ends- Enquiries: Oxford Biomedica plc John Dawson, Chief Executive OfficerStuart Paynter, Chief Financial OfficerCatherine Isted, Head of Corporate Development & IR T: +44 (0)1865 783 000T: +44 (0)1865 783 000T: +44 (0)1865 954 161 / E: ir@oxb.com Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal T: +44 (0)20 3709 5700 About Oxford Biomedica Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com
- Globe Newswire
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19 Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes AstraZeneca PLC (“AstraZeneca”) announced AZD1222 met primary efficacy endpoint in preventing COVID-19. Key highlights from the announcement were as follows: Two different dosing regimens demonstrated efficacy with one showing a better profileNo hospitalisations or severe cases of COVID-19 in participants treated with AZD1222One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given two full doses at least one month apartNo serious safety events related to the vaccine have been confirmedAstraZeneca will now immediately prepare regulatory submission of data to authorities around the world that have a framework in place for conditional or early approval To view the full announcement from AstraZeneca, please follow this link: (LINK) As announced on 1 September, Oxford Biomedica signed an 18 month supply agreement under a three year Master Supply and Development Agreement with AstraZeneca for large-scale commercial manufacture of their COVID-19 vaccine candidate, AZD1222. Under the terms of the agreement, AstraZeneca paid Oxford Biomedica £15 million upfront as a capacity reservation fee and the Group expects additionally to receive in excess of £35 million for large-scale manufacture of multiple batches of ADZ1222 until the end of 2021 subject to continuation of the programme. (LINK) John Dawson, Chief Executive Officer of Oxford Biomedica, said: “We are delighted to see the news today of the positive results from AstraZeneca for the COVID-19 vaccine, AZD1222. We are working hard to provide AstraZeneca with multiple large-scale batches of AZD1222 from our recently approved commercial manufacturing centre Oxbox. I am proud that Oxford Biomedica is part of the process that aims to bring normality back to many people around the world and I also personally want thank all our staff for their dedication and effort in production of the vaccine, whilst continuing to grow our core lentiviral vector business.” -Ends- Enquiries: Oxford Biomedica plc John Dawson, Chief Executive OfficerStuart Paynter, Chief Financial OfficerCatherine Isted, Head of Corporate Development & IR T: +44 (0)1865 783 000T: +44 (0)1865 783 000T: +44 (0)1865 954 161 / E: ir@oxb.com Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal T: +44 (0)20 3709 5700 About Oxford BiomedicaOxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com
- Fool.co.uk
I’d buy these 2 growth stocks for explosive returns!
Looking for top UK shares to buy now? These two biotech growth stocks have been generating explosive returns for many years. The post I’d buy these 2 growth stocks for explosive returns! appeared first on The Motley Fool UK.
